Start free

Agios Pharmaceuticals, Inc. (AGIO) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 28, 2026.

Filings shown
22
Open-market buys
0
Open-market sells
5

Counts cover the 22 most recent Form 4 filings Tradune holds for AGIO (filed Jun 16 – Oct 28, 2026); the score below covers only the trailing 90 days (0 buys, 3 sells). SEC EDGAR Form 4 filings for AGIO last checked Nov 21, 2026, 09:00 UTC; the latest AGIO filing Tradune holds was filed Oct 28, 2026. This is not guaranteed to be the complete record — see AGIO's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 2 filings Tradune holds for AGIO filed Oct 23 – Oct 28, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

3 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
3 sales· 9,855 sh
checkbox disclosed
On filings with the box not checked
0 sales· 0 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Sarah GheuensChief Medical Officer 0 3 — 9,855 −$371,112

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 3 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at AGIO

No open-market insider purchases (Form 4 code P) were reported for AGIO between Jun 16, 2026 and Oct 28, 2026. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Sarah Gheuens Chief Medical Officer · filed Oct 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 7,866 $37.69 54,645 −13% Oct 26, 2026
Option exercise Stock options (right to buy) 7,866 — — — Oct 26, 2026
Option exercise 7,866 $25.01 62,511 +14% Oct 26, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Sarah Gheuens Chief Medical Officer · filed Oct 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock options (right to buy) 500 — — — Oct 22, 2026
Open-market sale 10b5-1 box checked 500 $37.52 54,645 −0.9% Oct 22, 2026
Option exercise 500 $25.01 55,145 +0.9% Oct 22, 2026
Option exercise 1,489 $25.01 56,134 +2.7% Oct 21, 2026
Option exercise Stock options (right to buy) 1,489 — — — Oct 21, 2026
Open-market sale 10b5-1 box checked 1,489 $37.53 54,645 −2.7% Oct 21, 2026
Sarah Gheuens Chief Medical Officer · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 30,000 $30.48 54,645 −35% Aug 4, 2026
Jay T. Backstrom Director · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Restricted stock units 1,447 — — — Jul 8, 2026
Grant / award 1,447 — 1,447 — Jul 8, 2026
Sarah Gheuens Chief Medical Officer · filed Jul 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Restricted stock units 8,375 — — — Jul 1, 2026
Open-market sale 10b5-1 box checked 4,007 $37.56 84,645 −4.5% Jul 1, 2026
Option exercise 8,375 — 88,652 +10% Jul 1, 2026
Rahul D. Ballal Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Option exercise 2,816 — 15,230 +23% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Jeffrey D. Capello Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 2,816 — 10,865 +35% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Kaye I. Foster-Cheek Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Option exercise 2,816 — 10,284 +38% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Jacqualyn A. Fouse Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 2,816 — 154,156 +1.9% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Maykin Ho Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 2,816 — 19,848 +17% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Adams Catherine Owen Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Option exercise 2,816 — 10,865 +35% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
David Scadden Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Option exercise 2,816 — 20,419 +16% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Cynthia Smith Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 2,816 — 15,230 +23% Jun 18, 2026
Option exercise Restricted stock units 2,816 — — — Jun 18, 2026
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Krishnan Viswanadhan Chief Strategy and Operations · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Performance share units 3,000 — — — Jun 18, 2026
Grant / award Restricted stock units 3,000 — — — Jun 18, 2026
Brian Goff Chief Executive Officer · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Performance share units 39,000 — — — Jun 18, 2026
Grant / award Restricted stock units 39,000 — — — Jun 18, 2026
James William Burns Chief Legal Officer · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Performance share units 3,000 — — — Jun 18, 2026
Grant / award Restricted stock units 3,000 — — — Jun 18, 2026
Sarah Gheuens Chief Medical Officer · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Performance share units 3,000 — — — Jun 18, 2026
Grant / award Restricted stock units 3,000 — — — Jun 18, 2026
Cecilia Jones Chief Financial Officer · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Performance share units 3,000 — — — Jun 18, 2026
Grant / award Restricted stock units 3,000 — — — Jun 18, 2026
Tsveta Milanova Chief Commercial Officer · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Performance share units 3,000 — — — Jun 18, 2026
Grant / award Restricted stock units 3,000 — — — Jun 18, 2026
Jay T. Backstrom Director · filed Jun 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Restricted stock units 2,927 — — — Jun 18, 2026
Grant / award Stock options (right to buy) 14,950 — — — Jun 18, 2026
Adams Catherine Owen Director · filed Jun 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 1,976 — 8,049 +33% Jun 13, 2026
Option exercise Restricted stock units 1,976 — — — Jun 13, 2026
Jeffrey D. Capello Director · filed Jun 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Restricted stock units 1,976 — — — Jun 13, 2026
Option exercise 1,976 — 8,049 +33% Jun 13, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to AGIO's (Oct 28, 2026).

Frequently asked about AGIO insider activity

How many insiders bought AGIO stock in these Form 4 filings?

No open-market purchases (Form 4 code P) of AGIO shares were reported by Agios Pharmaceuticals, Inc. insiders between Jun 16, 2026 and Oct 28, 2026. The 22 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for AGIO?

The most recent Form 4 on this page was filed by Sarah Gheuens (Chief Medical Officer) on Oct 28, 2026, reporting 3 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market AGIO insider sale shown?

The largest open-market sale among the filings shown was 30,000 AGIO shares at $30.48 (about $914,400) by Sarah Gheuens (Chief Medical Officer) on Aug 4, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for AGIO — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.